MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-02-2023
Conformis Net Income 2011-2026 | CFMS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.5 M | -2.41 M | -24.3 M | -28.5 M | -43.4 M | -53.6 M | -57.6 M | -57.2 M | -45.7 M | -47.9 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.41 M | -57.6 M | -41.1 M |
Quarterly Net Income Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13 M | -9.57 M | - | -15.2 M | -15.5 M | -16 M | - | -13 M | 38 M | -11.5 M | -6.62 M | -6.18 M | -2.14 M | -9.35 M | -5.43 M | -8.7 M | -6.76 M | -7.58 M | -9.87 M | -7.44 M | -14.1 M | -12 M | -11.9 M | -12.5 M | -12.1 M | -17.2 M | -15.7 M | -12.8 M | -14.1 M | -15 M | -15 M | -17.1 M | -10.9 M | -14.3 M | -12.1 M | -10.4 M | -10.5 M | -12.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38 M | -17.2 M | -10.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
421 M | $ 186.04 | 0.73 % | $ 13.9 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 12.66 | -0.9 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bio-Rad Laboratories
BIO
|
-716 M | $ 296.5 | 1.38 % | $ 8.37 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.45 | 4.39 % | $ 129 M |  France |
 |
Bruker Corporation
BRKR
|
113 M | $ 39.67 | -0.56 % | $ 5.91 K | USA |
 |
Boston Scientific Corporation
BSX
|
2.89 B | $ 64.31 | 0.78 % | $ 95.2 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.6 | 1.34 % | $ 37.3 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 1.95 | -1.52 % | $ 1.19 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 10.47 | 0.87 % | $ 296 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 25.72 | 2.02 % | $ 217 M | USA |
 |
Inogen
INGN
|
-22.7 M | $ 6.29 | -0.79 % | $ 167 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.03 | -0.1 % | $ 17.4 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 6.17 | 2.15 % | $ 73.8 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
538 M | $ 94.65 | -0.29 % | $ 12.8 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 18.25 | 2.18 % | $ 428 M | USA |
 |
Butterfly Network
BFLY
|
-72.5 M | $ 4.78 | 7.91 % | $ 1.01 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.79 | 0.09 % | $ 33.1 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 10.91 | 0.28 % | $ 391 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 57.62 | 1.34 % | $ 1.69 B | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 39.3 | -1.11 % | $ 1.22 B | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 65.53 | 0.83 % | $ 3.57 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 87.32 | -1.46 % | $ 3.03 B | USA |
 |
FONAR Corporation
FONR
|
12.4 M | $ 18.75 | -0.05 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 78.01 | -0.24 % | $ 45.6 B | USA |
 |
NanoVibronix
NAOV
|
-3.7 M | - | - | $ 1.08 M | USA |